Home NDC 69097-167 LAMIVUDINE
Product NDC 69097-167
11-digit product format 690970167
Labeler code 69097
Product ID 69097-167_65d03051-a84c-49d7-928b-515cb1769bec
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name LAMIVUDINE
Dosage form TABLET
Route ORAL
Labeler Cipla USA Inc.
Application ANDA077221
Marketing category ANDA
Marketing start 2017-03-03
Marketing end 0000-00-00
Substance LAMIVUDINE
Active strength 300 mg/1
Pharmacologic classes Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2020-12-31
Current FDA listing Historical FDA.report record
Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A077221-001 LAMIVUDINE LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 A077221-002 LAMIVUDINE LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 2 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 3 · 86 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-03-09 01:35 UTC 2022-03 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 782e0a99824c…2021-12-28 21:50 UTC 2021-12 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 87673890dc5c…2021-03-12 10:30 UTC 2021-03 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 3f01610625f2…2019-12-14 00:12 UTC 2019-12 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 3f01610625f2…2019-09-15 20:21 UTC 2019-09 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 b00525d2431f…2019-09-15 20:21 UTC 2019-09 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 b00525d2431f…2019-07-19 19:46 UTC 2019-07 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 ea99ee380514…2019-07-19 19:46 UTC 2019-07 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 6a51e52b5d6a…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 1c564ffb4f44…2024-02-18 07:12 UTC 2024-02 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 ea1830bbd6c7…2023-12-20 04:57 UTC 2023-12 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 a72a2bbeb626…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 9b2671bbb829…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 a67488948f0b…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 3f0d92c62455…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 053a50430f4f…2023-05-13 08:27 UTC 2023-05 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 053a50430f4f…2023-01-26 05:58 UTC 2023-01 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 3bdfa0b2c4d7…2023-01-26 05:58 UTC 2023-01 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 3a93d1ddd44b…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 A077221-001 LAMIVUDINE 150MG TABLET / ORAL AB 2017-03-03 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 A077221-002 LAMIVUDINE 300MG TABLET / ORAL AB 2017-03-03 f41ea6bd6efb…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 3 · 86 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 69097-167 LAMIVUDINE TABLET [CIPLA USA INC.] 9 Legacy NDC 20190610_36b83d9a-962f-4821-bf44-0bace705b620.zip
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 69097-167-02 69097016702 30 TABLET in 1 BOTTLE (69097-167-02) 30 tablet 2017-03-03 0000-00-00 No No Current